Form 4: OnKure Therapeutics Director Andrew Phillips Granted Stock Options

OnKure Therapeutics, Inc. Director Andrew John Phillips was granted 7,650 stock options with an exercise price of $2.44, vesting based on continued service.

Summary

• Andrew John Phillips, a Director of OnKure Therapeutics, Inc. (OKUR), was granted 7,650 stock options.
• The transaction date for this grant was May 28, 2025.
• Each stock option has an exercise price of $2.44.
• The options are for Class A Common Stock, with each option representing the right to buy one share.
• The options will vest 100% on the earlier of May 28, 2026, or the day prior to the Issuer's next annual meeting of stockholders.
• Vesting is contingent upon Mr. Phillips continuing as a service provider through the applicable vesting date.
• The expiration date for these stock options is May 27, 2035.
• Following this transaction, Mr. Phillips beneficially owns 7,650 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The grant of stock options to a director is a positive sign of alignment between management/board and shareholders, incentivizing long-term performance. It's a routine compensation event, so the sentiment is moderately positive, reflecting standard corporate practice rather than extraordinary news.

Positives

• The grant of stock options aligns the interests of Director Andrew Phillips with those of shareholders, as his compensation is tied to the company's future stock performance.
• Equity compensation is a standard practice for attracting and retaining qualified directors and executives.

Risks

• The value of the stock options is dependent on the future market price of OnKure Therapeutics' Class A Common Stock exceeding the exercise price of $2.44.
• The options are subject to vesting conditions, meaning Mr. Phillips must continue as a service provider until the vesting date to realize the benefit.

Future Outlook

The stock options granted to Director Andrew Phillips are forward-looking, with their value and exercisability dependent on the company's future stock performance and his continued service until the vesting date, which is the earlier of May 28, 2026, or the day prior to the next annual meeting of stockholders.

Industry Context

The granting of stock options to directors is a common form of equity compensation across various industries, particularly in the biotechnology and pharmaceutical sectors where long-term value creation and retention of key talent are critical. This practice aims to align the interests of the board members with the long-term success and shareholder value of the company.

Comparison to Industry Standards

• The grant of stock options to directors is a standard compensation practice in the biotech industry, comparable to how companies like Moderna (MRNA) or BioNTech (BNTX) compensate their non-executive directors, often involving a mix of cash retainers and equity awards to incentivize long-term performance.
• The vesting schedule, tied to continued service and a specific future date or annual meeting, is typical for such grants, similar to equity compensation structures observed at companies like Gilead Sciences (GILD) or Amgen (AMGN) for their board members.

Related Party Transactions

• The grant of stock options to Andrew John Phillips, a Director of OnKure Therapeutics, Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The grant of options could lead to minor dilution if exercised, but it also aims to align the director's interests with long-term shareholder value creation.
• Director (Andrew John Phillips): Receives equity compensation, incentivizing his continued service and contribution to the company's success.

Next Steps

• The stock options will vest on the earlier of May 28, 2026, or the day prior to the Issuer's next annual meeting of stockholders, provided Andrew Phillips continues as a service provider.
• Upon vesting, Andrew Phillips will have the right to exercise the options to purchase Class A Common Stock at the exercise price of $2.44 per share until the expiration date of May 27, 2035.

Key Dates

Keywords

OnKure Therapeutics, OKUR, Stock Options, Director Compensation, Equity Grant, Insider Transaction, SEC Form 4, Beneficial Ownership